ClinicalTrials.gg
CompletedNCT02519855Updated Oct 30, 2018Results posted

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

A Phase 3 interventional study of ZOSTAVAX™ and Placebo to ZOSTAVAX™ in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
882
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
3rd of 29
882 · median 160
Started
2015
with 1 other
Phase 3
9 of 29
none open now
Registered
24th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 24th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age. The primary hypotheses tested 1) the noninferiority of concomitant versus nonconcomitant vaccination with regard to Varicella zoster virus (VZV) Geometric Mean Titer (GMT) antibody responses, 2) the acceptability of geometric mean fold rise in VZV antibody response after concomitant vaccination, and 3) the noninferiority of concomitant versus nonconcomitant vaccination with regard to influenza virus strain-specific GMT antibody responses.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has history of varicella or residence in a VZV-endemic area for ≥30 years
  • Is male, female not of , or female of reproductive potential and has a negative pregnancy test and agrees to avoid becoming pregnant throughout the study

Exclusion criteria

Exclusion Criteria:

  • Has history of to any vaccine component
  • Has previously received any varicella or zoster vaccine
  • Has received an influenza vaccine for the 2015-16 season
  • Has history of Herpes zoster
  • Has received immunoglobulin, monoclonal antibodies, or any blood products within 5 months before study vaccination
  • Is pregnant or breastfeeding, or expecting to conceive during the study
  • Has used therapy
  • Has known or suspected immune dysfunction
  • Has experienced Guillain-Barré syndrome within 6 weeks
  • Has severe thrombocytopenia or any other coagulation disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
882 participants (actual)

Study arms

  • Experimental
    Concomitant Vaccination

    ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4

    Biological: ZOSTAVAX™ · Biological: Placebo to ZOSTAVAX™ · Biological: Influenza Vaccine

  • Experimental
    Nonconcomitant Vaccination

    Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4

    Biological: ZOSTAVAX™ · Biological: Placebo to ZOSTAVAX™ · Biological: Influenza Vaccine

Interventions

  • BiologicalZOSTAVAX™

    A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)

    Also known as: V211

  • BiologicalPlacebo to ZOSTAVAX™

    A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)

  • BiologicalInfluenza Vaccine

    A single open-label administration of 0.5 mL intramuscular injection on Day 1

    Also known as: Fluzone, Vaxigrip

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody

    Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.

    Time frame: Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)

  2. Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers

    Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.

    Time frame: Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)

  3. Geometric Mean Titers of H1N1-specific Influenza Virus Antibody

    Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

    Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)

  4. Geometric Mean Titers of H3N2-specific Influenza Virus Antibody

    Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

    Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)

  5. Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody

    Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

    Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)

  6. Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody

    Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

    Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)

07

Results

Posted Feb 14, 2017

Participant flow

Participant flow — Overall Study
MilestoneConcomitant VaccinationNonconcomitant Vaccination
Started441441
Vaccinated on day 1440441
Vaccinated at week 4432424
Completed438437
Not completed34
Withdrew: Adverse event01
Withdrew: Lost to follow-up33

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody

Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.

Time frame:
Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody
gpELISA units/mLConcomitant VaccinationNonconcomitant Vaccination
Baseline, n=427, 409206.0 (185.6 to 228.6)230.5 (208.4 to 255.0)
Week 4, n=409, 392395.6 (363.7 to 430.4)482.0 (446.4 to 520.4)
Statistical analysis
  • Concomitant Vaccination vs Nonconcomitant Vaccination · Longitudinal regression model · p = <0.001 · Gmt ratio at 4 weeks postvaccination: 0.87 · 95% CI 0.80 to 0.95GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.
PrimaryGeometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers

Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.

Time frame:
Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)
Reported as:
Geometric mean · Ratio of titers (Week 4 / Baseline)
Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers
Ratio of titers (Week 4 / Baseline)Concomitant VaccinationNonconcomitant Vaccination
Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers1.9 (1.8 to 2.1)2.1 (1.9 to 2.2)
Statistical analysis
  • Concomitant Vaccination · Longitudinal regression · p = <0.001 (A lower bound of the 95% CI on the GMFR \> 1.4 indicated that the Concomitant Group induces an acceptable VZV antibody response. A p-value ≤0.025 also supported this conclusion.) · Gmfr from baseline: 1.90 · 95% CI 1.76 to 2.05Estimated GMFR, 95% CI and p-value were based on a longitudinal regression model adjusting for age.
PrimaryGeometric Mean Titers of H1N1-specific Influenza Virus Antibody

Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

Time frame:
Baseline and 4 weeks after Influenza vaccination (Week 4)
Reported as:
Geometric mean · Titer
Geometric Mean Titers of H1N1-specific Influenza Virus Antibody
TiterConcomitant VaccinationNonconcomitant Vaccination
Baseline, n=426, 42751.9 (45.4 to 59.3)50.1 (44.3 to 56.7)
Week 4, n=409, 405207.3 (185.6 to 231.7)200.5 (180.3 to 222.9)
Statistical analysis
  • Concomitant Vaccination vs Nonconcomitant Vaccination · Longitudinal regression · p = <0.001 · Gmt ratio at 4 weeks postvaccination: 1.02 · 95% CI 0.88 to 1.18GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.
PrimaryGeometric Mean Titers of H3N2-specific Influenza Virus Antibody

Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

Time frame:
Baseline and 4 weeks after Influenza vaccination (Week 4)
Reported as:
Geometric mean · Titer
Geometric Mean Titers of H3N2-specific Influenza Virus Antibody
TiterConcomitant VaccinationNonconcomitant Vaccination
Baseline, n=426, 42729.5 (26.2 to 33.3)31.1 (27.5 to 35.1)
Week 4, n=409, 405298.8 (264.1 to 338.1)272.0 (241.6 to 306.1)
Statistical analysis
  • Concomitant Vaccination vs Nonconcomitant Vaccination · Longitudinal regression · p = <0.001 · Gmt ratio at 4 weeks postvaccination: 1.10 · 95% CI 0.94 to 1.29GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.
PrimaryGeometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody

Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

Time frame:
Baseline and 4 weeks after Influenza vaccination (Week 4)
Reported as:
Geometric mean · Titer
Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody
TiterConcomitant VaccinationNonconcomitant Vaccination
Baseline, n=426, 42714.6 (13.3 to 16.1)12.6 (11.6 to 13.7)
Week 4, n=409, 40546.7 (42.0 to 52.0)43.9 (39.7 to 48.6)
Statistical analysis
  • Concomitant Vaccination vs Nonconcomitant Vaccination · Longitudinal regression · p = <0.001 · Gmt ratio at 4 weeks postvaccination: 1.00 · 95% CI 0.88 to 1.14GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.
PrimaryGeometric Mean Titers of B-Victoria-specific Influenza Virus Antibody

Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.

Time frame:
Baseline and 4 weeks after Influenza vaccination (Week 4)
Reported as:
Geometric mean · Titer
Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody
TiterConcomitant VaccinationNonconcomitant Vaccination
Baseline, n=426, 42711.2 (10.3 to 12.2)10.4 (9.6 to 11.2)
Week 4, n=409, 40533.9 (30.5 to 37.7)32.3 (29.0 to 35.9)
Statistical analysis
  • Concomitant Vaccination vs Nonconcomitant Vaccination · Longitudinal regression · p = <0.001 · Gmt ratio at 4 weeks postvaccination: 0.99 · 95% CI 0.87 to 1.13GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.

Adverse events

Collected over Up to 28 days after any vaccination (up to Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Concomitant Vaccination—4/435 (0.9%)256/435 (58.9%)
Nonconcomitant Vaccination—6/438 (1.4%)256/438 (58.4%)
Most frequent serious events
Most frequent serious events
EventConcomitant VaccinationNonconcomitant Vaccination
Chest painGeneral disorders1/4350/438
Biliary colicHepatobiliary disorders1/4350/438
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4350/438
Ureteric cancer localNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4350/438
Coronary artery diseaseCardiac disorders0/4351/438
Gastrointestinal toxicityGastrointestinal disorders0/4351/438
Lower gastrointestinal haemorrhageGastrointestinal disorders0/4351/438
OesophagitisGastrointestinal disorders0/4351/438
CholecystitisHepatobiliary disorders0/4351/438
Cerebrovascular accidentNervous system disorders0/4351/438
Most frequent other events
Most frequent other events
EventConcomitant VaccinationNonconcomitant Vaccination
Injection site painGeneral disorders209/435211/438
Injection site erythemaGeneral disorders153/435134/438
Injection site swellingGeneral disorders102/435109/438
Injection site pruritusGeneral disorders33/43532/438

Baseline characteristics

Participants are included as randomized

Age, Continuous
Age, Continuous(Years)Concomitant VaccinationNonconcomitant VaccinationTotal
Mean60.8 ± 7.261.3 ± 7.761.0 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Concomitant VaccinationNonconcomitant VaccinationTotal
Female266262528
Male174180354
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19. PubMed 28830693 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jan 2016, 4 months.

Results were first posted in Feb 2017, 1 year after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 4 months is below that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2015
First posted
Aug 11, 2015
StartActual
Sep 11, 2015
Primary completionActual
Jan 26, 2016
CompletionActual
Jan 26, 2016
Results first posted
Feb 14, 2017
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02519855
Responsible party
Sponsor
First posted
Aug 11, 2015
Start date
Sep 11, 2015
Primary completion
Jan 26, 2016
Completion
Jan 26, 2016
Results posted
Feb 14, 2017
Last update
Oct 30, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion